This page compares ibogaine and psilocybin as emerging treatments for post-traumatic stress disorder (PTSD). Both are psychedelic compounds under active clinical investigation, yet they differ substantially in mechanism, evidence base, risk profile, and practical access — distinctions that matter for anyone researching options.

At a Glance

Criterion Ibogaine Psilocybin
Primary Mechanism Multi-receptor (NMDA, opioid, sigma, serotonin); promotes GDNF/BDNF neuroplasticity Serotonin 5-HT2A agonist; default mode network disruption; BDNF upregulation
Evidence Level (PTSD) Preliminary — observational studies, small trials; no Phase III RCTs yet Preliminary — Phase II RCTs underway; broader psychedelic therapy evidence base
Session Duration 18–36 hours (single session) 4–8 hours (typically 2–3 sessions)
Legal Status (US) Schedule I federally; legal in some countries (Mexico, NZ, Gabon) Schedule I federally; decriminalized or regulated in Oregon, Colorado, Australia
Access Clinical trials; licensed retreats abroad Clinical trials; licensed service centers (Oregon, Colorado); retreats abroad
Estimated Cost $5,000–$15,000+ (retreat or clinic) $1,500–$5,000 (licensed service); higher at private retreats
Key Risks Cardiac arrhythmia, QT prolongation, fatalities reported; drug interactions Anxiety, psychosis risk in predisposed individuals; generally cardiovascular-safe
May Suit Treatment-resistant PTSD; comorbid opioid/stimulant dependence PTSD with depression; those seeking lower-risk psychedelic-assisted therapy

Mechanism of Action

Understanding how each compound works helps explain their distinct experiential and therapeutic profiles.

Ibogaine is a naturally occurring alkaloid from the Tabernanthe iboga shrub. Its pharmacology is unusually complex: it acts simultaneously as an NMDA receptor antagonist, a kappa- and mu-opioid receptor modulator, a sigma-2 receptor agonist, and a serotonin reuptake inhibitor. It also upregulates glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), which are linked to synaptic repair and neuroplasticity. For PTSD specifically, researchers hypothesize that ibogaine's dissociative, oneirogenic quality — producing vivid, life-review-like visions — may allow traumatic memories to be processed from a psychological distance. Its metabolite noribogaine has a long half-life (days to weeks), potentially extending neurobiological effects well beyond the acute session.

Psilocybin is a prodrug rapidly converted in the body to psilocin, a potent serotonin 5-HT2A receptor agonist. This receptor activation disrupts the default mode network (DMN) — a brain network associated with self-referential rumination — which many researchers believe underlies PTSD's ruminative and avoidance symptoms. Psilocybin also increases BDNF and promotes synaptogenesis, effects that may help reconsolidate traumatic memories. Its mechanism is more pharmacologically focused than ibogaine's, targeting serotonin pathways more selectively, which contributes to its comparatively cleaner safety profile.

Clinical Evidence for PTSD

Neither compound has completed Phase III randomized controlled trials specifically for PTSD, but the current evidence base differs meaningfully in size and study design.

Ibogaine and PTSD: The most cited dataset comes from a 2023 Stanford-affiliated observational study (Vermetten et al. / Amoroso et al.) of U.S. Special Operations veterans who received ibogaine treatment at a licensed clinic in Mexico. Of 30 participants, clinician-administered PTSD Scale (CAPS-5) scores dropped by an average of 88% at one-month follow-up, with improvements persisting at 12 months in a subset. Disability ratings, depression, and anxiety also improved significantly. While the results are striking, the absence of a control group, blinding, and randomization limits causal inference. Additional observational data from addiction contexts suggests ibogaine also reduces PTSD-related comorbid substance use, though rigorous PTSD-primary trials are sparse.

Psilocybin and PTSD: Psilocybin has been studied more broadly in trauma-adjacent conditions. Published Phase II trials in major depressive disorder (Carhart-Harris et al., NEJM 2021; Davis et al. 2021) show rapid and sustained antidepressant effects, and depression and PTSD share overlapping neurobiology. Dedicated Phase II PTSD trials — including a MAPS-affiliated study and an NYU trial — are actively enrolling or reporting results. Early open-label data and secondary analyses suggest psilocybin reduces PTSD symptom clusters including hyperarousal and emotional numbing. The broader evidence base for psilocybin-assisted therapy across conditions (depression, end-of-life anxiety, OCD) provides a larger safety and tolerability dataset than exists for ibogaine.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Safety and Risk Profile

Safety differences between ibogaine and psilocybin are substantial and clinically significant.

Ibogaine safety: Ibogaine's most serious risk is cardiotoxicity. It prolongs the cardiac QT interval, creating vulnerability to potentially fatal ventricular arrhythmias, including torsades de pointes. Fatalities have been documented — a 2021 review identified over 30 deaths associated with ibogaine, many linked to pre-existing cardiac conditions or drug interactions. Absolute contraindications include structural heart disease, long QT syndrome, and concurrent use of QT-prolonging drugs. Responsible programs require 12-lead ECG, comprehensive cardiac evaluation, and medical supervision throughout the extended session. Drug interactions are also a concern: ibogaine combined with opioids, stimulants, or certain SSRIs carries elevated risk. For PTSD populations — who carry high rates of polypharmacy, cardiovascular comorbidities, and substance use — screening is especially critical.

Psilocybin safety: Psilocybin has no established lethal dose in humans and is not associated with cardiac arrhythmia. The primary acute risks are psychological: anxiety, panic, and in rare cases psychosis, particularly in individuals with personal or family histories of schizophrenia or bipolar I disorder. Blood pressure rises transiently during sessions, warranting monitoring in those with hypertension. Psilocybin is not physically addictive and produces rapid tolerance, making misuse difficult. Hallucinogen persisting perception disorder (HPPD) is a rare but documented concern. When administered in structured, therapeutically supported settings, serious adverse events are uncommon across published trials.

Psychological intensity: Both compounds can produce deeply challenging experiences. Ibogaine's extended duration (up to 36 hours) and dissociative, vision-like quality can be particularly demanding, especially for trauma survivors. Psilocybin sessions are shorter and more amenable to interruption if distress escalates, though difficult experiences remain possible and are sometimes regarded therapeutically as part of the process.

Cost and Access

Practical access to either treatment remains limited, though the landscape is evolving.

Ibogaine access: In the United States, ibogaine is Schedule I with no approved therapeutic use and no licensed clinical pathway currently available domestically. Access primarily means traveling to licensed clinics or retreat centers in Mexico, Costa Rica, Jamaica, the Netherlands, or other jurisdictions where it is legal or unregulated. Costs typically range from $5,000 to $15,000 or more, reflecting the extended medical supervision required. Several U.S.-based research institutions are pursuing FDA-reviewed Phase II trials, which offer access for qualifying participants at no cost. Veterans' organizations, including the Veterans Exploring Treatment Solutions (VETS) nonprofit, have helped fund ibogaine treatment travel for eligible service members.

Psilocybin access: Oregon became the first U.S. state to license psilocybin service centers (Measure 109), with facilities operating since 2023. Colorado's Proposition 122 established a similar regulatory framework, with licensed centers expected to be operational by 2026–2027. Australian regulators approved authorized prescribers to administer psilocybin for treatment-resistant depression beginning in 2023. Internationally, retreat-based access exists in Jamaica, the Netherlands, and other countries. Costs at Oregon service centers currently range from approximately $1,500 to $4,000 per session, though insurance coverage is generally unavailable. Clinical trial participation remains the most affordable route in many cases.

Who Each Treatment May Suit

Available evidence points toward different candidate profiles, though individual assessment by qualified clinicians is always required.

Ibogaine may be considered by individuals with severe, treatment-resistant PTSD who have not responded to established therapies such as prolonged exposure, EMDR, or SSRI/SNRI pharmacotherapy. The compound's unique utility in simultaneously addressing comorbid opioid or stimulant dependence — common in trauma populations — distinguishes it from psilocybin. Veterans with complex trauma and substance use disorders have been the most studied group to date. However, the requirement for rigorous cardiac pre-screening, medical supervision, and geographic travel to legal jurisdictions creates meaningful barriers. Anyone with cardiac risk factors or current medication use involving QT-prolonging drugs may be ineligible.

Psilocybin may be considered by individuals with PTSD who also present with major depression, existential distress, or emotional numbing — symptom clusters where its serotonergic mechanism and growing evidence base are most relevant. Those who cannot tolerate the physical risks or logistical demands of ibogaine treatment may find psilocybin's comparatively favorable safety profile and shorter session duration more manageable. It is contraindicated in those with psychotic disorders or a strong family history of psychosis. As licensed service infrastructure grows in Oregon and Colorado, domestic access is improving without requiring international travel.

Key Difference

Ibogaine and psilocybin both represent a paradigm shift toward single-dose or few-dose psychedelic-assisted interventions for PTSD, but they occupy distinct positions in the risk-benefit landscape. Ibogaine's complex, multi-system pharmacology and dramatic preliminary results in veteran populations come paired with genuine cardiac danger that demands strict medical gatekeeping; psilocybin's more targeted serotonergic action, shorter sessions, and growing regulated access infrastructure make it more broadly approachable, though its PTSD-specific evidence base is still maturing. The two compounds are not interchangeable: they differ in duration, mechanism, safety requirements, legal availability, and the comorbidity profiles for which each appears most relevant.

Frequently Asked Questions

Neither compound has been approved as a PTSD treatment, and the word "cure" is not supported by current evidence. Observational and early clinical data show significant reductions in PTSD symptom scores — sometimes large and durable — but effect sizes vary, follow-up periods are often short, and placebo-controlled trials are still underway. Both are best understood as investigational treatments with promising but preliminary evidence.
Ibogaine produces a prolonged (18–36 hour) experience often described as oneirogenic — featuring vivid, waking-dream-like visions and a biographical life review that users report as confronting but meaningful. Physical effects including ataxia and nausea are common. Psilocybin sessions last 4–8 hours and are typically described as emotionally intense, visionary, and sometimes mystical, with physical side effects generally milder. Both can involve psychological difficulty; ibogaine's longer duration makes it harder to navigate if distress arises.
This is a serious safety concern. Many SSRIs and psychiatric medications prolong the QT interval or interact with ibogaine's pharmacology, potentially increasing cardiac risk. Most reputable ibogaine programs require a supervised taper off relevant medications before treatment — a process that itself carries risks and requires medical oversight. Psilocybin's interaction with SSRIs is different: serotonergic medications may blunt its psychedelic effects rather than creating direct cardiac danger, though this is also an active area of research. Neither treatment should be combined with psychiatric medications without direct medical guidance.
Both are in early stages for PTSD specifically. Ibogaine's most cited PTSD data comes from a compelling but methodologically limited 2023 observational study in veterans. Psilocybin has a larger overall clinical trial dataset across conditions (depression, end-of-life anxiety) and dedicated PTSD Phase II trials are currently reporting results, but PTSD-specific published RCT data remains limited for both compounds. The overall evidence base for psilocybin-assisted therapy is broader; ibogaine's PTSD-specific preliminary effect sizes in veteran populations are notably large.
Ibogaine remains Schedule I federally in the U.S. with no licensed domestic treatment pathway currently available. Veterans seeking ibogaine most commonly travel to licensed clinics in Mexico. Some nonprofit organizations provide financial assistance for this travel. Psilocybin has a growing domestic access pathway: Oregon's licensed service centers are operational, and Colorado's framework is developing. Veterans may also qualify for clinical trials of either compound at U.S. research institutions. VA facilities do not currently provide either treatment.
Integration support — helping participants make sense of and apply insights from their experience — is considered an important component of both treatments, though practices vary across programs. Psilocybin-assisted therapy as studied in clinical trials formally includes preparatory sessions before and integration sessions after the drug experience. Ibogaine programs vary more widely: some include structured integration therapy, others offer limited support. Researchers and clinicians generally agree that psychological support before and after sessions improves outcomes and safety for both compounds.
For ibogaine, significant cardiac conditions — including pre-existing QT prolongation, structural heart disease, arrhythmias, or use of cardiac medications — typically represent contraindications or require extremely careful evaluation. The cardiac risk is real and documented. For psilocybin, the cardiac risk profile is substantially lower; it does cause transient blood pressure and heart rate increases, so individuals with severe uncontrolled hypertension or certain cardiovascular conditions may warrant caution or closer monitoring, but it does not carry the arrhythmia risk associated with ibogaine. Individual assessment by a cardiologist familiar with these compounds is advisable in either case.
Psilocybin is further along the FDA clinical trial pipeline for relevant indications. Compass Pathways and Usona Institute have both conducted or are conducting Phase IIb/III trials for psilocybin in treatment-resistant depression and major depressive disorder respectively, which could eventually inform a PTSD pathway. The FDA granted psilocybin Breakthrough Therapy designation for both conditions. Ibogaine's cardiac risk profile presents a significant regulatory hurdle; while it has received some research interest and there are active Phase II investigations, a near-term FDA approval pathway for ibogaine faces more substantial safety-related challenges. Timelines for any psychedelic FDA approval remain uncertain.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.